Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.
San-Juan R, Fernández-Ruiz M, López-Medrano F, Carretero O, Lalueza A, Maestro de la Calle G, Pérez-Jacoiste Asín MA, Bueno H, Caro-Teller JM, Catalán M, de la Calle C, García-García R, Gómez C, Laguna-Goya R, Lizasoáin M, Martínez-López J, Origüen J, Sevillano Á, Gutiérrez E, de Miguel B, Aguilar F, Parra P, Ripoll M, Ruiz-Merlo T, Trujillo H, Pablos JL, Paz-Artal E, Lumbreras C, Aguado JM; H12O Immunomodulation Therapy for COVID-19 Group, the Spanish Network for Research in Infectious Diseases (REIPI).
San-Juan R, et al. Among authors: carretero o.
Int J Infect Dis. 2022 Apr;117:56-64. doi: 10.1016/j.ijid.2022.01.040. Epub 2022 Jan 23.
Int J Infect Dis. 2022.
PMID: 35081417
Free PMC article.